CA2368618A1 - Method of enhancing the efficacy of anti-tumor agents - Google Patents
Method of enhancing the efficacy of anti-tumor agents Download PDFInfo
- Publication number
- CA2368618A1 CA2368618A1 CA002368618A CA2368618A CA2368618A1 CA 2368618 A1 CA2368618 A1 CA 2368618A1 CA 002368618 A CA002368618 A CA 002368618A CA 2368618 A CA2368618 A CA 2368618A CA 2368618 A1 CA2368618 A1 CA 2368618A1
- Authority
- CA
- Canada
- Prior art keywords
- tumor agent
- erythropoietin
- cisplatin
- hematocrit
- elevator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
A method for enhancing the effect of anti-tumor agents on solid tumors is provided. The method comprises administering to an individual an anti-tumor agent and a hematocrit elevator. The hematocrit elevator may be administered before or concurrently with the anti-tumor agent.
Claims (13)
1. A method of improving the efficacy of an anti-tumor agent comprising the steps of administering to an individual in need of treatment (a) a chemotherapeutically effective amount of the anti-tumor agent; and (b) a hematocrit elevator, wherein the combination of the anti-tumor agent and the hematocrit elevator has a synergistic anti-tumor effect.
2. The method of claim 1, wherein the anti-tumor agent comprises a platinum compound.
3. The method of claim 2, wherein the anti-tumor agent is a malonato platinum compound.
4. The method of claim 3, wherein the malonato platinum compound is selected from the group consisting of cisplatin and carboplatin.
5. The method of claim 4, wherein the platinum compound is cisplatin.
6. The method of claim 4, wherein the platinum compound is carboplatin.
7. The method of claim 1, wherein the hematocrit elevator is selected from the group consisting of erythropoietin and erythropoietin-like substance.
8. The method of claim 7, wherein the hematocrit elevator is erythropoietin.
9. The method of claim 8, wherein the hematocrit elevator is an erythropoietin-like substance.
10. The method of claim 1, wherein the anti-tumor agent is cisplatin and the hematocrit elevator is erythropoietin.
11. The method of claim 10, wherein the cisplatin is administered in a dose of between 25 mg/m2 to 300 mg/m2.
12. The method of claim 11, wherein the cisplatin is administered in a dose of between 50 mg/m2 to 100 mg/m2.
13. The method of claim 1, wherein the hematocrit elevator is administered prior to the anti-tumor agent.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/300,124 | 1999-04-27 | ||
US09/300,124 US6171620B1 (en) | 1999-04-27 | 1999-04-27 | Method of enhancing the efficacy of anti-tumor agents |
PCT/US2000/011000 WO2000064455A1 (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2368618A1 true CA2368618A1 (en) | 2000-11-02 |
CA2368618C CA2368618C (en) | 2011-03-01 |
Family
ID=23157813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2368618A Expired - Fee Related CA2368618C (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Country Status (18)
Country | Link |
---|---|
US (3) | US6171620B1 (en) |
EP (1) | EP1212068A4 (en) |
JP (1) | JP2002542296A (en) |
KR (1) | KR100693796B1 (en) |
CN (1) | CN1188137C (en) |
AU (1) | AU781301B2 (en) |
BG (1) | BG64940B1 (en) |
BR (1) | BR0010082A (en) |
CA (1) | CA2368618C (en) |
HU (1) | HUP0200840A3 (en) |
IL (1) | IL146012A0 (en) |
MX (1) | MXPA01010899A (en) |
NO (1) | NO20015227L (en) |
NZ (1) | NZ514521A (en) |
PL (1) | PL350918A1 (en) |
RU (1) | RU2271829C2 (en) |
WO (1) | WO2000064455A1 (en) |
ZA (1) | ZA200108012B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001250221B2 (en) | 2000-04-26 | 2006-07-06 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
ATE466085T1 (en) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES |
EP2368553B1 (en) | 2003-04-08 | 2014-12-31 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
DE10361813A1 (en) * | 2003-12-30 | 2005-09-08 | Bionethos Holding Gmbh | Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
WO2006096626A2 (en) * | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057325A1 (en) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
AR057035A1 (en) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
JP2010510794A (en) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | Modified erythropoietin polypeptide and therapeutic use thereof |
MX351611B (en) | 2007-03-29 | 2017-10-20 | Wyeth Llc | Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof. |
JP5461386B2 (en) | 2007-03-29 | 2014-04-02 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | Peripheral opioid receptor antagonists and uses thereof |
ES2540551T3 (en) | 2007-03-29 | 2015-07-10 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
EP2730578A1 (en) | 2008-02-06 | 2014-05-14 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnal trexone |
EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
EP2310038A4 (en) * | 2008-05-15 | 2012-03-14 | Edison Pharmaceuticals Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
PL230756B1 (en) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Pharmaceutical set and application of erythropoietin and of the Bruton kinase inhibitor |
JPWO2019083023A1 (en) * | 2017-10-26 | 2020-11-12 | 国立大学法人 筑波大学 | Compositions for use in the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
JP2632014B2 (en) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | Bone marrow dysfunction anemia treatment |
JPH1067678A (en) * | 1996-06-20 | 1998-03-10 | Chugai Pharmaceut Co Ltd | Medicinal composition for treating liver disease |
US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1999
- 1999-04-27 US US09/300,124 patent/US6171620B1/en not_active Expired - Fee Related
-
2000
- 2000-04-24 KR KR1020017012929A patent/KR100693796B1/en not_active IP Right Cessation
- 2000-04-24 MX MXPA01010899A patent/MXPA01010899A/en active IP Right Grant
- 2000-04-24 PL PL00350918A patent/PL350918A1/en not_active Application Discontinuation
- 2000-04-24 EP EP00926315A patent/EP1212068A4/en not_active Withdrawn
- 2000-04-24 CN CNB008065659A patent/CN1188137C/en not_active Expired - Fee Related
- 2000-04-24 CA CA2368618A patent/CA2368618C/en not_active Expired - Fee Related
- 2000-04-24 AU AU44863/00A patent/AU781301B2/en not_active Ceased
- 2000-04-24 WO PCT/US2000/011000 patent/WO2000064455A1/en active IP Right Grant
- 2000-04-24 JP JP2000613446A patent/JP2002542296A/en active Pending
- 2000-04-24 HU HU0200840A patent/HUP0200840A3/en unknown
- 2000-04-24 NZ NZ514521A patent/NZ514521A/en not_active IP Right Cessation
- 2000-04-24 BR BR0010082-0A patent/BR0010082A/en not_active Application Discontinuation
- 2000-04-24 IL IL14601200A patent/IL146012A0/en unknown
- 2000-04-24 RU RU2001131894/14A patent/RU2271829C2/en not_active IP Right Cessation
- 2000-12-19 US US09/740,501 patent/US6426094B2/en not_active Expired - Fee Related
-
2001
- 2001-09-28 ZA ZA200108012A patent/ZA200108012B/en unknown
- 2001-10-25 NO NO20015227A patent/NO20015227L/en not_active Application Discontinuation
- 2001-10-26 BG BG106057A patent/BG64940B1/en unknown
-
2002
- 2002-07-26 US US10/206,533 patent/US6620779B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP0200840A2 (en) | 2002-07-29 |
IL146012A0 (en) | 2002-07-25 |
CN1188137C (en) | 2005-02-09 |
EP1212068A1 (en) | 2002-06-12 |
KR100693796B1 (en) | 2007-03-12 |
US6426094B2 (en) | 2002-07-30 |
BG64940B1 (en) | 2006-10-31 |
AU781301B2 (en) | 2005-05-12 |
RU2271829C2 (en) | 2006-03-20 |
CA2368618C (en) | 2011-03-01 |
MXPA01010899A (en) | 2003-06-24 |
BG106057A (en) | 2002-04-30 |
JP2002542296A (en) | 2002-12-10 |
KR20020000557A (en) | 2002-01-05 |
NO20015227L (en) | 2001-12-27 |
US20010000730A1 (en) | 2001-05-03 |
NZ514521A (en) | 2003-07-25 |
BR0010082A (en) | 2002-01-15 |
US6171620B1 (en) | 2001-01-09 |
ZA200108012B (en) | 2003-03-26 |
PL350918A1 (en) | 2003-02-10 |
CN1352561A (en) | 2002-06-05 |
HUP0200840A3 (en) | 2003-04-28 |
AU4486300A (en) | 2000-11-10 |
US20020198153A1 (en) | 2002-12-26 |
US6620779B2 (en) | 2003-09-16 |
NO20015227D0 (en) | 2001-10-25 |
EP1212068A4 (en) | 2007-03-14 |
WO2000064455A1 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2368618A1 (en) | Method of enhancing the efficacy of anti-tumor agents | |
CA2326761A1 (en) | Antitumor agent | |
RU2001131894A (en) | METHOD FOR INCREASING EFFICIENCY OF ANTITUMOR AGENTS | |
CA2294247A1 (en) | Antioxidant enhancement of therapy for hyperproliferative conditions | |
KR900002784A (en) | Pharmaceutical binding agents for use in antitumor therapy | |
CA2334267A1 (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
CA2261500A1 (en) | Stable oxaliplatin solutions and their use in cytostatic antineoplastic treatment | |
NO20024586D0 (en) | Method and preparations to prevent hormone-induced side effects | |
TR199701150T1 (en) | A pharmaceutical composition containing N-chlorophenyl carbamates, N-chlorophenylthiocarbamates and N-phosphonoglycine derivatives for inhibiting the development of viruses and cancers in mammals. | |
CA2388939A1 (en) | Therapeutic treatments for blood cell deficiencies | |
CA2002859A1 (en) | Method of treating epithelial disorders | |
WO1992019617A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
CA2673449A1 (en) | A combination comprising combretastatin and anticancer agents | |
RU99107569A (en) | PHARMACEUTICAL COMPOSITIONS Possessing Antimicrobial Activity | |
AU3245489A (en) | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer | |
WO2005039554A3 (en) | Therapeutic use of methionine for the treatment or prevention of mucositis | |
CA2334527A1 (en) | Combination of selenium-containing compounds with cytostatics | |
WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
CA2108330A1 (en) | Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin | |
MY122052A (en) | Method of treating tourette''s syndrome | |
CA2206566A1 (en) | Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds | |
CA2283739A1 (en) | Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy | |
WO2001070184A3 (en) | A composition containing monoterpenes for topical oral administration | |
WO2002076393A3 (en) | Antiagionecic, antitumor, chemopreventative agents | |
DK0669826T3 (en) | (-) - Metrifonate-containing drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |